Find Funding Opportunities

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support transformative discoveries that will lead to breakthroughs in understanding human brain function. Guided by the long-term scientific plan, BRAIN 2025: A Scientific Vision, this FOA specifically seeks to support efforts that will revolutionize our understanding of the biological activity underlying, and bioinformatic content of, data collected using contemporary non-invasive functional brain imaging techniques. The hope is that these transformative discoveries will lead to breakthroughs in understanding the dynamic activity of the human brain.

The purpose of this FOA is to solicit applications for an Epilepsy Center without Walls (CWOW) focused on collaborative preclinical and clinical research to prepare for translational and clinical development of disease modifying or prevention therapies for epilepsy. An additional goal is to develop community partnerships and community resources to advance development of such therapies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for projects to transfer technology out of the NIH intramural research labs into the private sector. If selected for SBIR funding, the SBC will be granted a royalty-free, non-exclusive patent license agreement for internal research use for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that the SBC will develop the invention into a commercial product to benefit the public.

The purpose of the NINDS Child Neurologist Career Development Program (CNCDP) is to facilitate and support the research career development of child neurologists, at educational institutions or professional organizations, who have made a commitment to independent research careers.The CNCDP is a single national program, implemented by either a single PD/PI or multiple co- directors (at least one of whom is the PD/PI), together with an advisory committee composed of basic and clinical investigators who have a strong record of funded research and successful training of clinician scientists. The CNCDP will generally provide three consecutive years of support to individuals to provide them with the knowledge, tools and research experience that will enable them to develop a significant research project funded by an individual career development award or research grant.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality. Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch. Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation. This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs). The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities. Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the parent R01 FOA, PA-13-302.

This FOA invites applications proposing to study health disparities in Alzheimers disease (AD) and related disorders. Health-disparities research related to AD should include the study of biological, behavioral, sociocultural, and environmental factors that influence population level health differences. Research approaches of interest include 1) improving recruitment and retention of populations underrepresented in AD research, 2) identifying priority factors or locating pathways and mechanisms that create and sustain AD health disparities, 3) addressing the challenges faced by informal/family caregivers from diverse racial, ethnic and socioeconomic backgrounds that are associated with the growing population of individuals with Alzheimers Disease, and 4) understanding the disparities in access to and utilization of formal long-term supports and services for those with dementia.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical study (e.g., Early Feasibility Study). The small clinical study should provide data to answer key questions about the function or final design of a device.This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical study is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical study.

This FOA is intended to facilitate partnerships between clinical investigators and manufacturers of latest-generation stimulating and/or recording devices that are FDA-designated as Class III (invasive, posing significant risk of harm), to conduct clinical research in the central nervous system.As part of The BRAIN InitiativeSM, NIH has initiated a Public-Private Partnership program (BRAIN PPP) to reduce barriers to negotiating such partnerships, and to ensure that new clinical studies leverage manufacturers existing data demonstrating safety and utility of these devices.Safety and utility data for invasive devices are costly to obtain, yet they are necessary for regulatory approval of human research, and therefore pose a substantial barrier to research progress.For this program, NIH has entered into agreements with a number of manufacturers to make available next generation devices that can stimulate and/or record from the central nervous system and have sufficient data to enable new Non-Significant Risk (NSR) or Investigational Device Exemption (IDE) without the need for significant additional testing.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical study to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study).Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants.The clinical study should provide data to answer key questions about the function or final design of a device.This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval.The clinical study is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical study to answer key questions about the function or final design of a device.

This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers. Projects should engage in one or more of the following activities: propagation of cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery. Applications focused on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of resources. Use of existing technologies to develop new reagents or genetic lines of clear value may be appropriate. Projects should address compelling needs of broad communities of neuroscience researchers or should offer unique services that otherwise would be unavailable. Projects must support the NINDS mission.